MegaPro Biomedical Co., Ltd (6827.TWO)
TWD 9.25
(-5.61%)
TWD 9.25
(-5.61%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -99.69 Million | -82.79 Million | -85.03 Million | -156.29 Million | - |
| Net Income | -127.55 Million | -111.28 Million | -89.15 Million | -148.86 Million | - |
| Depreciation & Amortization | 16.61 Million | 13.55 Million | 7.53 Million | 6.01 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 15.72 Million | 20.21 Million | 3.62 Million | - | - |
| Change in working capital | 298 Thousand | 695 Thousand | -9.4 Million | -12.16 Million | - |
| Other non-cash items | -4.8 Million | -2.38 Million | -1.1 Million | -2.22 Million | - |
| Investing Cash Flow | 18.78 Million | 56.4 Million | -85.28 Million | 177.33 Million | - |
| Investments in PPE | -4.38 Million | -13.5 Million | -17.91 Million | -7.51 Million | - |
| Acquisitions | -17.34 Million | - | - | - | - |
| Investment purchases | -17.34 Million | 70.67 Million | -66.9 Million | 184.85 Million | 73.71 Million |
| Sales/Maturities of investments | 54.86 Million | 70.67 Million | -66.9 Million | 184.85 Million | - |
| Other Investing Activities | -14.36 Million | -960 Thousand | -483 Thousand | - | - |
| Financing Cash Flow | 62.86 Million | -2.51 Million | 245 Million | - | - |
| Debt repayment | - | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 65.47 Million | - | 245 Million | - | - |
| Other Financing Activities | -2.61 Million | - | - | - | 83.2 Million |
| Accounts receivables | 1.74 Million | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | -1.44 Million | - | - | - | - |
| Cash at beginning of period | 144.22 Million | 167.7 Million | 95.2 Million | 72.47 Million | - |
| Cash at end of period | 127.25 Million | 144.22 Million | 167.7 Million | 95.2 Million | - |
| Capital Expenditure | -4.38 Million | -13.5 Million | -17.91 Million | -7.51 Million | - |
| Effect of forex changes on cash | 1.08 Million | 5.42 Million | -2.18 Million | 1.69 Million | - |
| Net cash flow / Change in cash | -16.96 Million | -23.48 Million | 72.5 Million | 22.73 Million | - |
| Free Cash Flow | -104.08 Million | -96.3 Million | -102.94 Million | -163.81 Million | - |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -77.23 Million | -127.55 Million | -65.07 Million | -62.47 Million | -111.28 Million | -49.44 Million |
| Depreciation & Amortization | 8.62 Million | 16.61 Million | 8.34 Million | 8.27 Million | 13.55 Million | 7.8 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 15.72 Million | - | - | 20.21 Million | - |
| Change in working capital | -5.35 Million | 298 Thousand | 1.15 Million | -858 Thousand | 695 Thousand | 3.45 Million |
| Other non-cash items | 3 Million | -4.8 Million | 5.67 Million | 5.25 Million | -2.38 Million | -101 Thousand |
| Investing Cash Flow | 40.03 Million | 18.78 Million | 78.85 Million | -60.06 Million | 56.4 Million | 22.83 Million |
| Investments in PPE | -1.02 Million | -4.38 Million | -3.67 Million | -709 Thousand | -13.5 Million | -4.37 Million |
| Acquisitions | - | -17.34 Million | 10 Thousand | 10 Thousand | - | - |
| Investment purchases | - | - | 27.65 Million | -45 Million | 70.67 Million | - |
| Sales/Maturities of investments | 41.05 Million | 54.86 Million | 54.86 Million | - | 70.67 Million | 28.17 Million |
| Other Investing Activities | - | -14.36 Million | 1000.00 | -14.36 Million | -960 Thousand | -960 Thousand |
| Financing Cash Flow | 83.3 Million | 62.86 Million | 64.15 Million | -1.29 Million | -2.51 Million | -1.25 Million |
| Debt repayment | -109 Thousand | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 84.52 Million | 65.47 Million | 65.47 Million | - | - | - |
| Other Financing Activities | -1.33 Million | - | -1.31 Million | -1.29 Million | - | -1.25 Million |
| Accounts receivables | 34 Thousand | - | 570 Thousand | 1.17 Million | - | -1.78 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -5.38 Million | - | 586 Thousand | -2.03 Million | - | 5.23 Million |
| Cash at beginning of period | 127.25 Million | 144.22 Million | 37.49 Million | 144.22 Million | 167.7 Million | 158.62 Million |
| Cash at end of period | 182.58 Million | 127.25 Million | 127.25 Million | 37.49 Million | 144.22 Million | 144.22 Million |
| Capital Expenditure | -1.02 Million | -4.38 Million | -3.67 Million | -709 Thousand | -13.5 Million | -4.37 Million |
| Effect of forex changes on cash | - | 1.08 Million | - | - | 5.42 Million | - |
| Net cash flow / Change in cash | 55.32 Million | -16.96 Million | 89.76 Million | -106.73 Million | -23.48 Million | -14.39 Million |
| Free Cash Flow | -71.98 Million | -104.08 Million | -53.56 Million | -50.51 Million | -96.3 Million | -42.65 Million |
300133
ROX
FNR
002689
002415
SOBHA